Novo Nordisk confirms cyber breach after hackers access personal data

Despite the disruption, the company stressed that “our core business operations are not impacted and remain up and running.

Novo Nordisk’s CagriSema delivers strong Phase 3 results across REIMAGINE diabetes trials

Novo Nordisk's Zenagamtide shows strong HbA1c and weight loss benefits in phase II trial

Investigational once-weekly GLP-1 and amylin receptor agonist achieves up to 14.6% weight loss and significant blood sugar reductions

Novo Nordisk launches Wegovy pill in UAE in first global rollout outside US

The move signals a major expansion in access to next-generation weight-loss therapies

Novo Nordisk to showcase late-stage pipeline & semaglutide expansion at ADA 2026

The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs

Novo Nordisk study exposes “hidden” inflammation driving cardio risk despite care

POSEIDON is among the largest global datasets to quantify this residual inflammatory burden

Novo Nordisk unveils breakthrough MASH data as ‘silent’ liver disease threatens 250 million

Wegovy delivers consistent weight loss & heart benefits for women across menopause: Novo Nordisk study

Nearly one in five women worldwide are now living with obesity

Novo Nordisk posts strong Q1 as Wegovy drives global GLP-1 momentum

The standout story remains Wegovy, particularly its new oral formulation

Novo Nordisk posts strong late-stage results for oral diabetes pill in children and teens

The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c